|
Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Dendreon |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics |
Research Funding - Janssen |
Patents, Royalties, Other Intellectual Property - UpToDate |
Other Relationship - Algeta ASA; Exelixis; Medivation; Sanofi |
|
|
Patents, Royalties, Other Intellectual Property - UpToDate Editor |
|
|
Travel, Accommodations, Expenses - ViewRay |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - GenomeDx |
|
|
Speakers' Bureau - Augmenix |
Travel, Accommodations, Expenses - Varian Medical Systems |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - GenomeDx |
|
Research Funding - GenomeDx; Medivation/Astellas |
Travel, Accommodations, Expenses - GenomeDx |
|
|
|
|
|
Speakers' Bureau - Genomic Health |
|
|
No Relationships to Disclose |